GLIP-M
Description
- Combination therapy for improved glycemic control in type 2 diabetes
- Teneligliptin 20 mg: Enhances insulin secretion and reduces glucagon
- Metformin 500 mg: Decreases liver glucose output and increases insulin sensitivity
- Targets both fasting and postprandial glucose levels
- Low risk of hypoglycemia and weight neutrality
- Supports HbA1c reduction and long-term diabetes management
- Convenient oral dosing improves patient compliance
Composition
TENELIGLIPTIN-20 MG, METFORMIN HYDROCHLORIDE-500MG
Benefits
GLIP-M delivers dual-action control of type 2 diabetes by combining two well-established mechanisms of action. It helps lower blood sugar levels effectively without significant risk of hypoglycemia and is weight-neutral. The combination supports reduction in HbA1c and helps prevent long-term diabetes-related complications. With once or twice-daily dosing, GLIP-M enhances treatment convenience and compliance for patients who require more than monotherapy to achieve target glycemic goals.
Introduction
GLIP-M is a fixed-dose combination of Teneligliptin 20 mg and Metformin Hydrochloride 500 mg, designed to provide comprehensive glycemic control in patients with type 2 diabetes mellitus. Teneligliptin is a DPP-4 inhibitor that enhances the activity of incretin hormones, thereby increasing insulin secretion and reducing glucagon levels in a glucose-dependent manner. Metformin, a first-line biguanide, decreases hepatic glucose production and improves peripheral insulin sensitivity. Together, GLIP-M offers a synergistic and effective approach to managing both fasting and postprandial blood glucose levels.
